Lunit will be presenting its research contributions at RSNA 2024, featuring a record-breaking 20 abstracts.

SEOUL, South Korea, Nov. 25, 2024 | WNPH | — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has announced its participation in the Radiological Society of North America (RSNA) 2024 Annual Meeting. The company will be presenting a total of 20 abstracts, showcasing its groundbreaking research and solutions that highlight the transformative role of AI in radiology. Lunit’s research emphasizes how AI can address critical challenges in healthcare, such as improving diagnostic accuracy and enhancing clinician efficiency.

Two notable research presentations from Lunit include:

1. A study led by Dr. Hari Trivedi from Emory University, focusing on Lunit INSIGHT DBT, an AI-powered solution for breast cancer detection using digital breast tomosynthesis (DBT) images. The research demonstrated Lunit AI’s consistent performance across various subgroups, including race, ethnicity, age, and breast density, with key findings showing robust overall AUC, high sensitivity, and specificity.

2. Another study presented by Dr. Ruchir Shah from Oxford University Hospitals evaluated the impact of Lunit INSIGHT CXR, an AI-powered solution for chest X-ray interpretation, on clinician performance in emergency and inpatient care settings. The study showed significant improvement in clinicians’ accuracy with AI assistance, particularly in detecting pulmonary nodules, pleural effusion, and fibrosis.

Lunit’s CEO, Brandon Suh, expressed excitement about the company’s participation in RSNA 2024 and highlighted how their AI solutions are reshaping the standard of care for diverse patient populations globally. The RSNA 2024 Annual Meeting will take place in Chicago, Illinois, from December 1-6, 2024. For more information, visit Lunit’s booth #4929 in the AI Showcase.

Lunit’s presentations at RSNA 2024 will feature the Lunit INSIGHT suite, covering various topics related to AI in mammography and chest X-ray interpretation. Lunit, founded in 2013, is a medical AI company dedicated to conquering cancer through accurate diagnosis and optimal treatment. The company’s FDA-cleared Lunit INSIGHT suite serves over 4,500 hospitals and medical institutions across 55+ countries. With a focus on breast health and screening technologies, Lunit continues to lead the global fight against cancer. Learn more at lunit.io